CTRI/2021/03/032236
Not yet recruiting
Phase 1
A double-blind randomised placebo-controlled study followed by an Open-label extension, comparative clinical study to evaluate the effect of PartySmart variants
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The Himalaya Drug Company
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Males aged between 20\-45 years, weighing more than 45 kgs
- •2Subject who used to drink alcohol regularly (social drink not alcohol abuse) and is willing and able to comply with the alcohol consumption requirements and overnight stay as per the study requirements
- •3\.Subjects judged by the Investigator to be in general good health based on medical history.
- •4\.Subject understands the study procedures and signs the consent forms providing informed consent to participate in the study
Exclusion Criteria
- •1\.Subject suspected for drug or alcohol abuse
- •2\.A medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
- •3\.Subjective sleep duration of less than 3 hours in the night before the test
- •4\.Caffeine, nicotine or alcohol on the day (from midnight) of the test
- •5\.Use of psycho\-active drugs during the past 30 days or any treatment that might interfere with the evaluation of the test drug
- •6\.Any drug known to interact with benzodiazepines and related drugs, e.g. antiepileptics, antihistaminics, muscle relaxant drugs, antihypertensive drugs, drugs inhibiting cytochrome P450
- •7\.Any clinically significant disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, neurological and or psychiatric disorder etc.)
- •8\.Known hypersensitivity to any of the ingredients of the study drugs
- •9\.Participation in any other clinical trial within the past 30 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A double-blind randomised placebo controlled study to evaluate the effects of different doses of testosterone from a Testosterone Metered-Dose Transdermal Spray (MDTS) on sexual function in premenopausal women with low libidoow libido in post menopausal women suffering from low serum testosteroneLow libido in post menopausal women suffering from low serum testosteroneReproductive Health and Childbirth - Menstruation and menopauseACTRN12605000481673FemPharm Pty Ltd and/or Acrux DDS Pty Ltd200
Active, not recruiting
Phase 2
A double-blind randomized placebo-controlled study of Desvenlafaxine for managing vasomotor symptoms in breast cancer survivorsVasomotor symptomsTCTR20210326006Khon Kaen University60
Completed
Not Applicable
A randomised double-blind placebo-controlled study of energy, protein and micronutrients supplementation of elderly patients in active rehabilitation settingsutritional status in the elderlyNutritional, Metabolic, EndocrineNutritional statusISRCTN01133608The Health Foundation (UK)445
Completed
Not Applicable
A randomised double-blind placebo-controlled study to investigate the possible role of Opiate Morphine (MST) in the treatment of chronic cough.ISRCTN18474014Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)30
Completed
Phase 3
A randomised double-blind placebo-controlled study to evaluate the effect ofcurcumin on BDNF levels in otherwise healthy adults.Brain-Derived Neurotrophic Factor in healthy adultsNeurological - Studies of the normal brain and nervous systemAlternative and Complementary Medicine - Other alternative and complementary medicineACTRN12621000104853RDC Global Pty Ltd69